Spyre Therapeutics (SYRE) Receivables - Accured: 2019-2025
Historic Receivables - Accured for Spyre Therapeutics (SYRE) over the last 5 years, with Sep 2025 value amounting to $3.6 million.
- Spyre Therapeutics' Receivables - Accured rose 111.76% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 111.76%. This contributed to the annual value of $3.4 million for FY2024, which is 277.78% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Receivables - Accured is $3.6 million, which was up 2.86% from $3.5 million recorded in Q2 2025.
- Spyre Therapeutics' Receivables - Accured's 5-year high stood at $3.6 million during Q3 2025, with a 5-year trough of $100,000 in Q3 2021.
- For the 3-year period, Spyre Therapeutics' Receivables - Accured averaged around $1.8 million, with its median value being $1.7 million (2024).
- Its Receivables - Accured has fluctuated over the past 5 years, first tumbled by 50.00% in 2021, then skyrocketed by 1,700.00% in 2024.
- Quarterly analysis of 5 years shows Spyre Therapeutics' Receivables - Accured stood at $100,000 in 2021, then remained steady at $100,000 in 2022, then spiked by 800.00% to $900,000 in 2023, then skyrocketed by 277.78% to $3.4 million in 2024, then spiked by 111.76% to $3.6 million in 2025.
- Its Receivables - Accured was $3.6 million in Q3 2025, compared to $3.5 million in Q2 2025 and $3.4 million in Q1 2025.